Psoriasis is a disease characterized by an imbalance between Th-1 and Th-17 and Th-2 inflammatory axes, in which cutaneous mesenchymal stem cells (MSCs) are early involved, as they show a greater relative expression of several genes encoding for Th-1 and Th-17 cytokines. Therapeutic implications of TNF- inhibitors on differentiated skin cells have been largely described in psoriasis; however, their effects on MSCs derived from patients with psoriasis have been only partially described. The aim of this work was to evaluate the effect of TNF- inhibitors on cytokine milieu expressed by MSCs isolated from the skin of patients with psoriasis. Resident MSCs from skin of patients with psoriasis and healthy subjects have been isolated, characterized and profiled by PCR and ELISA for the expression of 22 cytokines involved in Th-1, Th-2 and Th-17 pathways, both before and after 12weeks therapy with TNF- inhibitors. The administration of TNF- inhibitors for 12-weeks acts on MSCs as follows: it reduces the expression of several Th-1-Th-17 cytokines whose levels are elevated at baseline (IL-6, IL-8, IL-12, IL-23A, IFN-, TNF-, CCL2, CCL20, CXCL2, CXCL5, IL-17A, IL-17C, IL-17F, IL-21, G-CSF). Similarly, it enhances the expression of several Th-2 cytokines which are underexpressed at baseline (IL-2, IL-4, IL-5), reducing the expression of those overexpressed at baseline (TGF- and IL-13). TNF- inhibitors could contribute to reduce the pathological imbalance between the Th-1-Th-17 vs Th-2 axis in MSCs of patients with psoriasis.